Trial · NCT07903025
Evaluation of the Axomove Therapy Medical Device to Facilitate Adapted Physical Activity for Patients With Obesity
NCT07903025, Not applicable, Not yet recruiting, Axomove
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Evaluation of the Axomove Therapy Medical Device to Facilitate Adapted Physical Activity for Patients With Obesity. Trials, record NCT07903025. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07903025
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Evaluation of the Axomove Therapy Medical Device to Facilitate Adapted Physical Activity for Patients With Obesity
- NCT number
- NCT07903025
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 184 participants, estimated
- Lead sponsor
- Axomove
- Conditions
- Obese Adults
- Interventions
- Axomove Therapy, Standard multidisciplinary medical care
- First posted
- 2026-10-29
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes27
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Distance walked in the 6-Minute Walk Test | At Month 0 = the patient's enrollment date (within a 2-week window prior to discharge from the hospital), and at Month 6 = 6 months (+/-15 days) | The 6-Minute Walk Test is the most commonly used test to assess functional capacity. It will be administered by trained healthcare personnel (other than the investigator). It is performed over a distance of at least 30 meters on a flat surface. Each patient will receive the same instructions to walk as far as possible for 6 minutes, with the option to walk back and forth along this corridor. The outcome measure reports the total distance walked (expressed in meters) over 6 minutes. Measurements will be taken using the same device, following the same procedure. The test should preferably be conducted in the morning or, if not possible, always at the same time of day for the same participant. Participants must wear comfortable clothing and shoes suitable for walking. Standard walking aids (canes, walkers, etc.) may be used if necessary. |
| Secondary | Body weight | At Month 0 = the patient's enrollment date (within a 2-week window prior to discharge from the hospital), and at Month 6 = 6 months (+/-15 days) | Weight is measured in kilograms (kg) using standard calibrated clinical scales across study sites. |
| Secondary | Waist circumference | At Month 0 = the patient's enrollment date (within a 2-week window prior to discharge from the hospital), and at Month 6 = 6 months (+/-15 days) | Waist circumference is measured in centimeters (cm) according to standardized clinical procedures across study sites. |
| Secondary | Body composition | At Month 0 = the patient's enrollment date (within a 2-week window prior to discharge from the hospital), and at Month 6 = 6 months (+/-15 days) | Body composition is assessed using bioimpedance analysis (BIA). The ratio is expressed as a unitless continuous variable, where a lower ratio indicates a higher proportion of muscle relative to fat mass (representing an improved body composition). |
| Secondary | Level of physical activity | At Month 0 = the patient's enrollment date (within a 2-week window prior to discharge from the hospital), and at Month 6 = 6 months (+/-15 days) | Physical activity levels will be assessed using the International Physical Activity Questionnaire - Short Form (IPAQ-SF). The questionnaire evaluates the frequency and duration of vigorous activity, moderate activity, and walking over the past 7 days. Total physical activity is expressed as a continuous score in MET-minutes per week (ranging from 0 to unbounded, where higher scores indicate higher levels of physical activity). It also allows categorical classification into low (\< 600 MET-min/week), moderate (600 to 2,999 MET-min/week), or high (≥ 3,000 MET-min/week) activity levels. |
| Secondary | Pain | At Month 0 = the patient's enrollment date (within a 2-week window prior to discharge from the hospital), and at Month 6 = 6 months (+/-15 days) | Pain will be assessed using the EVA pain scale, a visual analog scale ranging from 0 to 10 (from no pain to the worst pain imaginable). |
| Secondary | Kinesiophobia | At Month 0 = the patient's enrollment date (within a 2-week window prior to discharge from the hospital), and at Month 6 = 6 months (+/-15 days) | The TSK-17 (Tampa Scale for Kinesiophobia-17 items) assesses kinesiophobia, or the irrational fear of movement. It evaluates beliefs and attitudes related to movement, avoidance, and risk perception. The original version consists of 17 items (there is also a short 11-item version), using a 4-point Likert scale ranging from 1 ("strongly disagree") to 4 ("strongly agree"). The higher the score, the greater the level of kinesiophobia (a score of 40/68 is considered indicative of significant kinesiophobia) |
| Secondary | Health-Related Quality of Life in the context of obesity | At Month 0 = the patient's enrollment date (within a 2-week window prior to discharge from the hospital), and at Month 6 = 6 months (+/-15 days) | Quality of life is assessed using the QOLOD (Quality of Life, Obesity, and Dietetics) test, which is recognized as a simple and reliable tool for specifically evaluating health-related quality of life in the context of obesity and dietary treatment in France, and is recommended for clinical practice by various healthcare professionals. The QOLOD scale consists of 36 items divided into 5 dimensions (physical, psychosocial, sexual life, dietary well-being, and experience with dietary treatment). Each question is rated on a Likert scale from 1 (Extremely/Always) to 5 (Not at all/Never). Scores are converted to percentages (0-100%), with higher scores indicating a better quality of life |
| Secondary | Health-related quality of life | At Month 0 = the patient's enrollment date (within a 2-week window prior to discharge from the hospital), and at Month 6 = 6 months (+/-15 days) | Health-related quality of life is evaluated using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire. The instrument consists of two parts: 1. EQ-5D-5L Descriptive System: Covers 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each rated on a 5-point scale from 1 ("no problems") to 5 ("extreme problems"). These responses are converted into a single summary Index Score ranging from less than 0 (health state worse than death) to 1.000 (perfect health), where higher scores indicate a better health-related quality of life. 2. EQ Visual Analog Scale (EQ-VAS): A continuous scale ranging from 0 ("the worst health you can imagine") to 100 ("the best health you can imagine"), where higher scores indicate a better self-rated overall health status. |
| Secondary | Anxiety and depression | At Month 0 = the patient's enrollment date (within a 2-week window prior to discharge from the hospital), and at Month 6 = 6 months (+/-15 days) | Anxiety and depression are assessed using the HAD (Hospital Anxiety and Depression Scale). It is a self-report scale designed to screen for anxiety and depression in hospitalized or outpatient patients. It consists of 14 items divided into two subscales: anxiety (HAD-A) and depression (HAD-D), each comprising seven questions. Each item is scored on a scale of 0 to 3, resulting in a subscale score ranging from 0 to 21. A score of 0 to 7 is considered normal, 8 to 10 is considered borderline, and a score of 11 or higher is considered indicative of a probable disorder. |
1 to 10 of 27Source ClinicalTrials.gov
See all 27 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07903025
GET https://conductscience.org/api/trials/v1/NCT07903025/registered?page=2